Publications by authors named "E S Voronin"
A series of new types of composites (biopolymer-silica materials) are proposed as selective and effective adsorbents. A new procedure for the synthesis of chitosan-nanosilica composites (ChNS) and chitosan-silica gel composites (ChSG) using geometrical modification of silica and mechanosorption of chitosan is applied. The highest adsorption efficiency was achieved at pH = 2, hence the desirability of modifications aimed at stabilizing chitosan in such conditions.
View Article and Find Full Text PDFThe influence of the geometric modification (GM) of fumed nanoscale silica A300 (NS) on the adsorption capacity of human serum albumin (HSA) as well as the physicochemical and textural properties of the protein/nanosilica system was analyzed. An effective medical enterosorbent based on fumed nanosilica was designed and produced in the Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine. To design an effective nanomaterial for biomedical applications as a wound-healing material, the adsorption, physicochemical and surface properties of the initial nanosilica (NS), nanosilica after geometric modification (GM-nanosilica), and HSA/nanosilica biocomposites were characterized.
View Article and Find Full Text PDFOutcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
Antivir Ther
June 2022
Article Synopsis
- Etravirine (ETR) is used for second or third-line antiretroviral treatment in children with HIV, and a study assessed its outcomes in children across Europe and Thailand.
- Data was collected from 177 children, showing that 69% achieved viral suppression after 12 months and experienced an increase in CD4 cell counts; however, 46% discontinued ETR due to reasons such as treatment simplification and failure.
- Some adverse events were reported, including rare but serious reactions like Stevens-Johnson Syndrome, but overall, ETR proved effective for many treatment-experienced children.
Article Synopsis
- Bictegravir combined with emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective and well-tolerated HIV treatment, showing no resistance in treatment-naive and suppressed patients for 48 weeks.* -
- In a phase 3 trial, 472 women with suppressed HIV were randomly assigned to either switch to B/F/TAF or continue their current regimen, with results demonstrating that switching was as effective as staying on the original treatment.* -
- The study highlights B/F/TAF as a safe option for women living with HIV, providing essential insights into the efficacy and tolerability of antiretroviral therapy specifically for this group.*
Background: Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not contain sex-specific treatment. We aimed to assess the safety and efficacy of the single tablet integrase inhibitor regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted protease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.
View Article and Find Full Text PDF